$CRDL Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference

TORONTO, Sept. 9, 2026 /CNW/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("**Cardiol**" or the "**Company**"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, on September 14, 2026, at 10:30 a.m. EDT.

**H.C. Wainwright 28th Annual Global Investment Conference**
When: Monday, September 14 at 10:30 a.m. EDT.
Where: Lotte New York Palace Hotel, in the Louis Room (4th Floor)
A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website ([www.cardiolrx.com/investors/events-presentations/](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4769758-1&h=2952057016&u=https%3A%2F%2Fwww.cardiolrx.com%2Finvestors%2Fevents-presentations%2F&a=www.cardiolrx.com%2Finvestors%2Fevents-presentations%2F)).

**About Cardiol Therapeutics**
Cardiol Therapeutics Inc. (**NASDAQ: CRDL**) (**TSX: CRDL**) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

Read full release: https://finance.yahoo.com/healthcare/articles/cardiol-therapeutics-participate-fireside-chat-112700700.html